
EU reportedly in talks with J&J to secure doses of its COVID-19 vaccine
pharmafile | June 19, 2020 | News story | Medical Communications, Research and Development, Sales and Marketing |Â Â COVID-19, EU, Europe, J&J, JJ, VaccineÂ
It has been reported that the European Union is currently negotiating a deal with pharma giant Johnson & Johnson to reserve or buy upfront the COVID-19 vaccine the latter currently has in development.
The reports originated from the testimonies of two European Union health officials, Reuters reported. But due to the confidential nature of the discussions, forthcoming details on the potential deal were scarce.
The European Commission declined to comment on the story. Johnson & Johnson has been transparent about its efforts working with national governments and international organisation in its development of a vaccine candidate to combat COVID-19, but would not elaborate on speculation around a deal with the EU.
The pharma firm is set to push its candidate into human trials in July. It is anticipated that the deal between the company and the EU could be revealed as early as next week, but it is currently closely under wraps and there’s still a chance it could fall through.
If the story transpires to be true, the deal would mark the first partnership signed under the €2 billion emergency fund mandated by the EU across all 27 member states. The fund is designed to fund and secure the procurement of COVID-19 vaccine candidates from up to six different developers.
Matt Fellows
Related Content

BioNet receives positive EMA opinion on new pertussis vaccine
BioNet has received a positive opinion from the Committee for Medicinal Products for Human Use …

Sharp invests $100m in US and EU manufacturing and packaging facilities
Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across …

Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON
Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based …






